Day One Biopharmaceuticals, Inc. has built its growth trajectory largely around the commercialization of OJEMDA™ (tovorafenib) for pediatric low-grade glioma, a niche but impactful oncology area. Revenue surged by over 20% in 2025, supported by this FDA-approved product and strategic licensing deals with Ipsen for markets outside the U.S. Losses narrowed somewhat due to improved operating performance, yet significant cash burn persists as the company invests in ongoing clinical trials. A pending $2.5 billion acquisition offer from Servier Pharmaceuticals reflects Day One's specialized pipeline potential but introduces regulatory and shareholder approval uncertainties ahead.